Avid Bioservices, Inc. (CDMO)
- Previous Close
10.34 - Open
10.17 - Bid 10.49 x 100
- Ask 10.57 x 100
- Day's Range
10.15 - 10.54 - 52 Week Range
4.07 - 12.48 - Volume
349,997 - Avg. Volume
737,881 - Market Cap (intraday)
672.4M - Beta (5Y Monthly) 1.39
- PE Ratio (TTM)
-- - EPS (TTM)
-2.29 - Earnings Date Dec 5, 2024 - Dec 9, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
13.50
Avid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is based in Tustin, California.
www.avidbio.comRecent News: CDMO
View MorePerformance Overview: CDMO
Trailing total returns as of 11/5/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CDMO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CDMO
View MoreValuation Measures
Market Cap
659.64M
Enterprise Value
832.22M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.60
Price/Book (mrq)
11.25
Enterprise Value/Revenue
5.85
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-101.27%
Return on Assets (ttm)
-3.05%
Return on Equity (ttm)
-115.84%
Revenue (ttm)
142.36M
Net Income Avi to Common (ttm)
-144.16M
Diluted EPS (ttm)
-2.29
Balance Sheet and Cash Flow
Total Cash (mrq)
36.78M
Total Debt/Equity (mrq)
353.77%
Levered Free Cash Flow (ttm)
-201.62k